Recombinant HIV gp41 L protein

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The protein target HIV gp41 L also known simply as gp41 is a glycoprotein of approximately 41 kDa. It plays a mechanical role in the fusion process during the entry of the Human Immunodeficiency Virus (HIV) into host cells. gp41 facilitates the fusion of the viral and host cell membranes a critical step in viral infection. This protein is a component of the envelope glycoprotein complex expressed on the surface of the virion and after its attachment to the host cell becomes important for the virus to enter the cell.

Biological function summary

The role of gp41 in the HIV lifecycle involves mediating the fusion between the viral envelope and the host cell membrane. This protein acts in tandem with another viral envelope glycoprotein gp120 forming a complex that is essential for HIV to attach and gain entry into the host cell. gp41 undergoes significant conformational changes upon interaction with the host cell receptor enabling the fusion of the viral and cellular membranes. The protein has become an important target for antiretroviral therapies due to its central role in infection.

Pathways

The entry of HIV into the host cell is the main pathway where gp41 is involved. It is intricately linked to the viral entry pathway where the protein helps the virus navigate past the host's cellular defenses. This action not only involves gp41 but also implicates gp120 which binds to the CD4 receptor on host cells triggering the exposure and subsequent action of gp41. This pathway represents a prime target for therapeutics aimed at intercepting the early stages of viral infection.

Gp41 is directly associated with the progression of HIV and the consequent development of Acquired Immunodeficiency Syndrome (AIDS). The protein's ability to mediate viral entry is critical for the virus's propagation within the host leading to immune system compromise. We can observe its significant interaction with the CD4 receptor and coreceptors which are important in the pathogenesis of these conditions. Blocking gp41's function through inhibitors has shown potential in slowing down the progression of the disease highlighting its relevance in therapeutic strategy development.